ClinicalTrials.gg
CompletedNCT03168256Updated Jun 28, 2022

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

A Phase 3 interventional study of CF101 2mg and CF101 3mg in Plaque Psoriasis, sponsored by Can-Fite BioPharma. Completed at 30 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-06-28.

Sponsored by Can-Fite BioPharma · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
528
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies in Psoriasis with a site in Bulgaria — 1 open to participants now, 4 under way, 4 of them phase 3. Psoriasis · Bulgaria.

Enrollment
23rd of 46
528 · median 509
Started
2018
with 1 other
Phase 3
30 of 46
1 open now
Registered
28th of 46
by date
Lead sponsor
2 of 46
Can-Fite BioPharma

Among the 46 studies in Psoriasis with a site in Bulgaria, this one is the 23rd largest by enrollment, is one of 2 that started in 2018, is one of 30 in phase 3, and was the 28th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 46 studies in Psoriasis with a site in Bulgaria is open now. Recruiting first, the newest first:

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Psoriasis with a site in Bulgaria, or all of them as a file.
02

Study summary

This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve signs and symptoms of the disease. CF101 effect will be in comparison to apremilast in this study population

Read the detailed description

This is a multicenter, randomized, double-blind, placebo- and active-controlled, study in adult males and females, aged 18 to 80 years, inclusive, with a diagnosis of moderate-to-severe chronic plaque psoriasis.

Eligible subjects will be randomly assigned to CF101 2 mg, 3 mg, matching apremilast 30 mg BID, or matching placebo, in a 3:3:3:2 ratio. Blinding will be maintained using a double-dummy technique.

Medication will be taken orally BID for 32 weeks in a double-blinded fashion, with the option to continue treatment through an Extension Period to 48 weeks. Subjects initially assigned to the placebo group will be re-randomized at Week 16 to either CF101 2 mg, CF101 3 mg, or apremilast (with appropriate dose titration) in a 1:1:1 ratio and treated through Week 32, while subjects originally assigned to 1 of the active treatment groups will remain on that treatment through Week 32. The primary efficacy endpoint will be assessed at Weeks 16 and 32; at Week 32, all subjects will be offered the opportunity to remain on their assigned blinded drug through Week 48 (ie, the Extension Period of Weeks 33-48).

Disease will be assessed using PASI , static PGA , the percentage of BSA involved, and PDI. Subjects will return for assessments and a new supply of study medication at Weeks 4, 8, 12, 16, 20, 24, and 28, and for final study assessments at Week 32. For those subjects continuing into the Extension Period, efficacy and safety assessments will also occur at Weeks 36, 40, 44, and 48. PK will be assessed in a subgroup of approximately 120 subjects at Weeks 0, 8, 16, 24 and 32. PK will be assessed through sparse sampling. Assessment of whole blood A3AR expression levels will occur at Screening, Week 16, and Week 32.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 to 80 years of age, inclusive;
  2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement ≥10%, as judged by the Investigator;
  3. PASI score ≥12 (Appendix 3)
  4. Static PGA ≥3 (Appendix 2)
  5. Candidate for systemic treatment or phototherapy for psoriasis;
  6. Duration of psoriasis of at least 6 months;
  7. Elevated whole blood A3AR expression level, defined as ≥ 1.5-fold over a predetermined normal population standard at Screening;
  8. Females of must have a negative serum pregnancy test at screening;
  9. Females of child-bearing potential must be willing to use 2 methods of deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method) to be eligible for, and continue participation in, the study;
  10. Ability to complete the study in compliance with the protocol; and
  11. Ability to understand and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Psoriasis limited to erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis in the absence of plaque psoriasis;
  2. Prior treatment with apremilast within 4 weeks prior to the Baseline visit, or to apremilast;
  3. Treatment with systemic retinoids, , tofacitinib, or agents (e.g., methotrexate, cyclosporine) within 4 weeks of the Baseline visit;
  4. Treatment with a biological agent (etanercept, adalimumab, efalizumab, infliximab, ustekinumab, alefacept, secukinumab, or others, including agents) within a period of time equal to 5 times its circulating half-life, or 30 days, whichever is longer, prior to the Baseline visit;
  5. Treatment with high potency topical dermatological corticosteroids (Class I-III in US, Class III-IV in Europe), Vitamin D analogs, keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit;
  6. Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period;
  7. Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit, or anticipated need for such drugs during the study period, unless dose has been stable for 3 months prior to the Screening visit and will remain stable throughout the trial;
  8. Serum creatinine level greater than 1.5 times the laboratory's at Screening;
  9. Liver aminotransferase levels greater than 1.5 times the laboratory's upper limit of normal at Screening;
  10. (ECG) at Screening shows abnormalities which, in the judgment of the Investigator, are and could, in the judgment of the Principal Investigator, compromise subject safety;
  11. Active gastrointestinal disease which could interfere with the absorption of oral medication;
  12. Pregnancy, planned pregnancy, lactation, or inadequate as judged by the Investigator;
  13. Active drug or alcohol dependence;
  14. History of depression or suicidal ideation within the past year;
  15. Concomitant use of strong cytochrome P450 inducers, eg, rifampin, phenobarbital, phenytoin, carbamazepine;
  16. Previous participation in a CF101 clinical trial;
  17. Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
  18. Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to the Screening visit.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
528 participants (actual)

Study arms

  • Experimental
    CF101 2mg

    CF101 2mg, orally q12 hours

    Drug: CF101 2mg

  • Experimental
    CF101 3mg

    CF101 3mg, orally q12 hours

    Drug: CF101 3mg

  • Active comparator
    Apremilast 30mg

    Apremilast 30mg, orally q12 hours

    Drug: Apremilast 30mg

  • Placebo comparator
    Placebo

    Placebo control , orally q12 hours

    Drug: Placebo Oral Tablet

Interventions

  • CF101 tablets, 2mg BID for 16 weeks

    Also known as: IB-MECA

  • CF101 tablets, 3mg BID for 16 weeks

    Also known as: IB-MECA

  • Apremilast tablets, 30mg BID for 16 weeks

    Also known as: Otezla

  • DrugPlacebo Oral Tablet

    Placebo tablets, BID for 16 weeks

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) at Week 16

    Evaluate the efficacy of oral CF101 2 mg or 3 mg twice daily (BID) in patients with moderate-to-severe plaque psoriasis, compared with placebo, as determined by the proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) at Week 16 (superiority)

    Time frame: 16 weeks

  2. Adverse event profile in this patient popluation

    Nature, incidence and severity of treatment-emergent adverse events

    Time frame: 16 weeks

Secondary outcomes

  1. Psoriasis Area and Severity Index (PASI) score response of ≥50% (PASI 50) at Week 16

    Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve PASI 50 at Week 16 (superiority);

    Time frame: 16 weeks

  2. Physician Global Assessment (PGA)

    Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve PGA score of 0 or 1 at Week 16;

    Time frame: 16 weeks

  3. Psoriasis Disability Index (PDI)

    Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve improvement on the PDI at Week 16;

    Time frame: 16 weeks

  4. CF101 PASI 75 compare to apremilast

    Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PASI 75 at Weeks 16 and 32;

    Time frame: weeks 16-32

  5. CF101 PGA score compare to apremilast

    Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PGA score of 0 or 1, at Weeks 16 and 32;

    Time frame: weeks 16-32

  6. CF101 PASI 50 compare to apremilast

    Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PASI 50 at Weeks 16 and 32;

    Time frame: weeks 16-32

  7. CF101 PDI improvement compare to apremilast

    Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve an improvement in PDI at Weeks 16 and 32;

    Time frame: weeks 16-32

  8. Apremilast PASI 75 compare to placebo

    Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PASI 75, PGA score of 0 or 1, PASI 50, and improvement in PDI at Week 16 (superiority);

    Time frame: weeks 16-32

  9. Apremilast PGA compare to placebo

    Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PGA score of 0 or 1 at Week 16;

    Time frame: weeks 16-32

  10. Apremilast PASI 50 compare to placebo

    Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PASI 50 at Week 16;

    Time frame: weeks 16-32

  11. Apremilast PDI compare to placebo

    Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve improvement in PDI at Week 16;

    Time frame: 16 weeks

  12. Adverse event profile of piclidenoson through the Extension Period of up to 48 weeks of treatment

    Nature, incidence, and severity of treatment-emergent adverse events

    Time frame: 48 weeks

  13. Efficacy of piclidenoson, as determined by changes in PASI score, through the Extension Period of up to 48 weeks of treatment

    The proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) at Week 48

    Time frame: 48 weeks

  14. Determine pharmacokinetics (PK) of piclidenoson under the circumstances of this trial using sparse sampling

    Serum concentration of piclidenoson

    Time frame: 48 weeks

  15. Evaluate the relationship between pre-treatment whole blood A3 adenosine receptor (A3AR) expression levels and response to piclidenoson treatment.

    Explore the relationship between white blood cell (WBC) adenosine A3 receptor (A3AR) expression and treatment response, by taking WBC sample at baseline

    Time frame: 16 weeks

07

Study locations

30 sites
  • Clinical Centre of Republika Srpska
    Banja Luka, Bosnia and Herzegovina
  • University Clinical Centre Mostar
    Mostar, Bosnia and Herzegovina
  • Clinical Centre of Sarajevo University
    Sarajevo, Bosnia and Herzegovina
  • "Multiprofile Hospital for Active Treatment - Pazardzhik"
    Pazardzhik, Bulgaria
  • "MHAT"Rahila Angelova"AD, Department of Skin and Venereal Diseases
    Pernik, Bulgaria
  • "University Multiprofile Hospital for Active Treatment - D-r Georgi Stranski" - EAD, Pleven, Clinic of Skin and Venereal Diseases
    Pleven, Bulgaria
  • "Diagnostic-Consultative Aleksandrovska" EOOD
    Sofia, Bulgaria
  • "Diagnostic-Consultative Centre XX - Sofia" EOOD
    Sofia, Bulgaria
  • Ambulatory for Specialized Medical Help - Group Practice Dermatology - Clinic EuroDerma" OOD
    Sofia, Bulgaria
  • K. Papp Clinical Research
    Waterloo, Canada
  • Clinical Hospital Center Rijeka
    Rijeka, Croatia
  • Sestre milosrdnice University Hospital Center
    Zagreb, Croatia
  • Rambam Medical Center
    Haifa, Israel
  • Institutul de Cardiologie
    Chisinau, Moldova, Republic of
  • Spitalul Clinic Municipal Nr. 3 "Sfanta Treime"
    Chisinau, Moldova, Republic of
  • Spitalul Clinic Republican
    Chisinau, Moldova, Republic of
  • Centrum Usług Medycznych MaxMed
    Bochnia, Poland
  • Gdańskim Centrum Zdrowia
    Gdańsk, Poland
  • Miejski Szpital Zespolony Klinika Dermatologii Chorób Przenoszonych Drogą Płciową i Immunologii klinicznej
    Olsztyn, Poland
  • ETG Zamość, ul. Szczebrzeska 11i
    Zamość, Poland
  • All-MED Centrum Medyczne
    Łódź, Poland
  • Lubelskie Centrum Diagnostyczne
    Świdnik, Poland
  • Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL
    Braşov, Romania
  • SC PELICAN Impex SRL
    Oradea, Romania
  • Spitalul Clinic Județean de Urgență Sibiu
    Sibiu, Romania
  • Clinical Centre of Serbia
    Belgrade, Serbia
  • Clinical Centre Nis
    Niš, Serbia
  • Military Hospital Nis
    Niš, Serbia
  • General Hospital Sremska Mitrovica
    Sremska Mitrovica, Serbia
  • General Hospital Zajecar
    Zaječar, Serbia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Jan 2022, 39 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 39 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
May 30, 2017
StartActual
Sep 15, 2018
Primary completionActual
Jan 6, 2022
CompletionActual
Apr 27, 2022
Last update
Jun 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03168256
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
May 30, 2017
Start date
Sep 15, 2018
Primary completion
Jan 6, 2022
Completion
Apr 27, 2022
Last update
Jun 28, 2022

Study contacts

Michael David, MD
principal investigator · Rabin Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion